The role of biomarkers in predicting treatment outcomes after therapy for high-grade squamous intraepithelial lesions and early-stage cervical cancer: a scoping review

Background High-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia (HSIL/CIN2–3) and early-stage cervical cancer require different treatments and have distinct recurrence and surveillance profiles. Biomarker research predicting treatment outcomes is fragmented across biomarker classes, specimen types, populations, and outcome definitions, with prognostic and predictive roles often conflated. This scoping review aimed to map research on biomarkers predicting treatment outcomes after therapy for HSIL/CIN2–3 and early-stage cervical cancer from 2000 to 2026, and to classify biomarkers as diagnostic, prognostic, predictive, or monitoring. Specifically, the review addressed three research questions: (1) which biomarkers have been evaluated against treatment outcomes for HSIL/CIN2–3 and for early-stage cervical cancer, and how do the two evidence bases compare; (2) how are these biomarkers distributed across diagnostic, prognostic, predictive, and monitoring roles; and (3) which biomarker categories are sufficiently mature and homogeneous to be considered candidates for future meta-analysis. Methods The review followed the Arksey and O'Malley framework, refined by Levac et al., and JBI methodology, and was reported according to PRISMA-ScR. MEDLINE/PubMed, Embase, Scopus, CINAHL, Cochrane CENTRAL, and Web of Science were searched for studies published from January 2000 to January 2026. Eligible studies evaluated viral, molecular, immunohistochemical, serum, radiologic, or immune biomarkers against treatment outcomes in women with HSIL/CIN2–3 or FIGO stage I–IIB2 cervical cancer. Two reviewers independently screened and charted data by population, biomarker class, specimen type, evidentiary role, and outcome. Findings were synthesized narratively and in tables without meta-analysis. Results Among 58 representative sources, HSIL studies mainly evaluated persistent/type-specific high-risk human papillomavirus (hrHPV) DNA, HPV E6/E7 mRNA, HPV integration, p16/Ki-67 dual staining, and host-gene methylation, predominantly as diagnostic, monitoring, or prognostic markers. In invasive cancer, the investigated biomarkers included serum SCC-Ag, circulating tumour HPV DNA, tumour-infiltrating lymphocytes, sentinel lymph node micrometastases, microRNAs, and PD-L1 combined positive score. Conclusion Biomarker research remains heterogeneous and is dominated by prognostic and monitoring applications, with limited evidence for genuinely predictive biomarkers. Standardized terminology, harmonized reporting, population-specific analyses, and treatment-comparison designs are needed to advance biomarker-guided individualized management.

Authors

Institutions

Publication Details

Journal
Oncology Reviews
Published
2026-11-17
DOI
https://doi.org/10.3389/or.2026.1967247
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The role of biomarkers in predicting treatment outcomes after therapy for high-grade squamous intraepithelial lesions and early-stage cervical cancer: a scoping review

Bridget Sharon Angucia, Nixon Niyonzima, Judith R. M. Mwansa-Kambafwile, Admire T Chikandiwa et al.
3 links
Oncology Reviews
Cervical Cancer and HPV Research
article

The role of biomarkers in predicting treatment outcomes after therapy for high-grade squamous intraepithelial lesions and early-stage cervical cancer: a scoping review

Bridget Sharon Angucia, Nixon Niyonzima, Judith R. M. Mwansa-Kambafwile, Admire T Chikandiwa, Langanani Mbodi, Absalom Mwazha, Robert F. Breiman, Henry Zakumumpa, Benjamin Mwesige
article en

Abstract

Background High-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia (HSIL/CIN2–3) and early-stage cervical cancer require different treatments and have distinct recurrence and surveillance profiles. Biomarker research predicting treatment outcomes is fragmented across biomarker classes, specimen types, populations, and outcome definitions, with prognostic and predictive roles often conflated. This scoping review aimed to map research on biomarkers predicting treatment outcomes after therapy for HSIL/CIN2–3 and early-stage cervical cancer from 2000 to 2026, and to classify biomarkers as diagnostic, prognostic, predictive, or monitoring. Specifically, the review addressed three research questions: (1) which biomarkers have been evaluated against treatment outcomes for HSIL/CIN2–3 and for early-stage cervical cancer, and how do the two evidence bases compare; (2) how are these biomarkers distributed across diagnostic, prognostic, predictive, and monitoring roles; and (3) which biomarker categories are sufficiently mature and homogeneous to be considered candidates for future meta-analysis. Methods The review followed the Arksey and O'Malley framework, refined by Levac et al., and JBI methodology, and was reported according to PRISMA-ScR. MEDLINE/PubMed, Embase, Scopus, CINAHL, Cochrane CENTRAL, and Web of Science were searched for studies published from January 2000 to January 2026. Eligible studies evaluated viral, molecular, immunohistochemical, serum, radiologic, or immune biomarkers against treatment outcomes in women with HSIL/CIN2–3 or FIGO stage I–IIB2 cervical cancer. Two reviewers independently screened and charted data by population, biomarker class, specimen type, evidentiary role, and outcome. Findings were synthesized narratively and in tables without meta-analysis. Results Among 58 representative sources, HSIL studies mainly evaluated persistent/type-specific high-risk human papillomavirus (hrHPV) DNA, HPV E6/E7 mRNA, HPV integration, p16/Ki-67 dual staining, and host-gene methylation, predominantly as diagnostic, monitoring, or prognostic markers. In invasive cancer, the investigated biomarkers included serum SCC-Ag, circulating tumour HPV DNA, tumour-infiltrating lymphocytes, sentinel lymph node micrometastases, microRNAs, and PD-L1 combined positive score. Conclusion Biomarker research remains heterogeneous and is dominated by prognostic and monitoring applications, with limited evidence for genuinely predictive biomarkers. Standardized terminology, harmonized reporting, population-specific analyses, and treatment-comparison designs are needed to advance biomarker-guided individualized management.

Oncology ReviewsVol. 20
National Health Laboratory Service (ZA), Emory University (US), University of the Witwatersrand (ZA), Uganda Cancer Institute (UG), National Cancer Registry (IE), Makerere University (UG), University of KwaZulu-Natal (ZA)
Carnegie Corporation of New York, Styrelsen för Internationellt Utvecklingssamarbete, European Commission, African Population and Health Research Center
Good health and well-being
Cervical Cancer and HPV Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon